Last reviewed · How we verify

NCT06268977

Using of SGLt2 Inhibitors in Patients With Type 2 DM

Status unknown Last updated 21 February 2024
What this trial tests

trial testing SGLT2 inhibitor in Type 2 Diabetes in 400 participants. Status unknown.

Timeline
1 March 2024
Primary endpoint
1 March 2025
30 March 2025

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 March 2024
Primary completion1 March 2025
Estimated completion30 March 2025

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 80, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To detect the efficacy of SGLT2i in improving the metabolic parameters in patients with type 2 diabetes. \- To detect the side-effects of SGLT2i

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of SGLT2 inhibitor

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06268977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing